<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055170</url>
  </required_header>
  <id_info>
    <org_study_id>HLC001</org_study_id>
    <nct_id>NCT02055170</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CancerCare Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CancerCare Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effect of hormone therapies (androgen pathway
      modification) on the outcomes of patients with lung cancer. This information may be of
      benefit for future treatment strategies, prevention and control.

      In this study, the protein where testosterone binds, called the androgen receptor (AR), will
      be measured in samples from the patient's biopsy and surgical tumor samples. The
      investigators will look at a marker of how fast the cancer is growing (Ki67) before using
      finasteride from your biopsy specimen. Finasteride will be taken from the day of consent
      until the day of the patient's surgery. This marker will be measured again after using
      finasteride from the surgical specimen. The investigators will be looking for a decrease in
      the Ki67 from the patient's biopsy specimen to the surgical specimen as an indicator that
      this medication is blocking tumour growth.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to improve on poor accrual to study.
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">March 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in proliferation</measure>
    <time_frame>Original biopsy to surgical specimen (approx 6 weeks)</time_frame>
    <description>Patients will be followed from time of consent (around the time of consultation with a Thoracic Surgeon) to date of surgery (on average, approximately 4-6 weeks following Thoracic Surgeon consultation).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>finasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>finasteride 5mg po od from study entry to date of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>finasteride 5mg oral daily</intervention_name>
    <arm_group_label>finasteride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male

          -  age &gt;18

          -  biopsy-proven non-small cell lung cancer

          -  surgical intervention planned

        Exclusion Criteria:

          -  current use of 5-alpha reductase inhibitor

          -  previous diagnosis of prostate cancer

          -  previous hypersensitivity to 5-alpha reductase inhibitor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 2, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

